Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Denmark continues exclusion of J&J, AstraZeneca COVID-19 vaccines

Fri, 25th Jun 2021 12:12

(Adds quote from J&J)

By Nikolaj Skydsgaard

COPENHAGEN, June 25 (Reuters) - Health authorities in
Denmark said on Friday that COVID-19 vaccines from AstraZeneca
and Johnson & Johnson would remain excluded from
the country's vaccine roll-out following a review of new safety
data.

"The balance between possible benefit and possible harmful
effects is still not favourable, even when we include
assumptions in our analyses that benefit the vaccine," the
Danish Health Authority said in a statement.

Denmark was the first country to suspend and altogether
ditch Johnson & Johnson's and AstraZeneca's vaccines in April
and May over safety concerns due to their potential link to a
very rare but serious form of blood clot.

Health authorities said then the benefits of the vaccines
did not outweigh the risks, especially since most of the elderly
population had already been inoculated and the epidemic was
largely under control.

The European Union's drug regulator has found a possible
link between the vaccines and an extremely rare form of blood
clotting, but says the benefits of the vaccines outweigh any
risks of side effects.

In late May, the Danish government asked health authorities
to reconsider the exclusion of those vaccines since new data on
their effects and side-effects had been reported.

Based on a review of fresh data from United States and the
European Union, the health agency said on Friday there was now a
certain link between both vaccines and so-called vaccine-induced
immune thrombotic thrombocytopenia (VITT).

It could not conclude whether the risk of suffering from
VITT-syndrome was lower, the same or higher after inoculation
with Johnson & Johnson's shot compared with AstraZeneca's
vaccine.

"On April 20th the EMA (European Medicines Agency) confirmed
a positive benefit-risk profile for use of the Janssen COVID-19
vaccine. The decision was informed by data and science," a
spokesperson for J&J's Janssen unit said in an emailed comment
to Reuters.

"We respect the independent decision made by the Danish
Health Authorities and will continue to collaborate closely with
them to provide all the information they require to continue
their investigations," she added.

The ditched vaccines have however been made available for
Danes on a voluntary basis following a doctor's consultation.
2.4% of people vaccinated have been fully vaccinated with J&J's
shot, while just 0.1% have received two doses of AstraZeneca's
vaccine.

Just over half of Denmark's population has received their
first shot, the vast majority of them with Pfizer-BioNTech's
, vaccine.
(Reporting by Nikolaj Skydsgaard and Jacob Gronholt-Pedersen;
Editing by William Maclean
Editing by Alison Williams, Edmund Blair and Frances Kerry)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.